HOMOLOGY MEDICINES, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 19th, 2018 • Homology Medicines, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 19th, 2018 Company Industry Jurisdiction
HOMOLOGY MEDICINES, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • March 19th, 2018 • Homology Medicines, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 19th, 2018 Company Industry JurisdictionTHIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20[18] between Homology Medicines, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).
Employment AgreementEmployment Agreement • March 19th, 2018 • Homology Medicines, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledMarch 19th, 2018 Company Industry JurisdictionThis Employment Agreement (this “Agreement”), dated as of March 18, 2018, is made by and between Homology Medicines, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Arthur O. Tzianabos (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
Confidential Treatment Requested by Homology Medicines, Inc. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 19th, 2018 • Homology Medicines, Inc. • Pharmaceutical preparations • California
Contract Type FiledMarch 19th, 2018 Company Industry JurisdictionTHIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into as of the 28th day of April, 2016 (the “Effective Date”) by and between Homology Medicines, Inc., a Delaware corporation with a principal place of business at 44 Hartwell Avenue, Suite 102, Lexington, Massachusetts 02421 (“Licensee”) and City of Hope, a California nonprofit public benefit corporation located at 1500 East Duarte Road, Duarte, California 91010 (“City of Hope” or “COH”). Licensee and COH are each sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN HOMOLOGY MEDICINES, INC. AND NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. DATED NOVEMBER 6, 2017Collaboration and License Agreement • March 19th, 2018 • Homology Medicines, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 19th, 2018 Company Industry JurisdictionTHIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into this 6th day of November, 2017 (the “Effective Date”), by and between Homology Medicines, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 45 Wiggins Avenue, Bedford, MA 01730 (“HMI”), and Novartis Institutes for BioMedical Research, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 250 Massachusetts Avenue, Cambridge, MA 02139 (“NVS”). HMI and NVS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENTLicense Agreement • March 19th, 2018 • Homology Medicines, Inc. • Pharmaceutical preparations • California
Contract Type FiledMarch 19th, 2018 Company Industry JurisdictionTHIS AGREEMENT is effective as of the 14th day of September, 2016 (the “Effective Date”), between the CALIFORNIA INSTITUTE OF TECHNOLOGY (“Caltech”), a not-for-profit corporation duly organized and existing under the laws of the State of California with an address at 1200 East California Boulevard, MC 6-32, Pasadena, California 91125 and HOMOLOGY MEDICINES, INC. (“Licensee”), a Delaware corporation having a place of business at 44 Hartwell Avenue, Suite 102, Lexington, Massachusetts 02421 (the “Parties”).